📊 TNGX Key Takeaways
Is Tango Therapeutics, Inc. (TNGX) a Good Investment?
Tango Therapeutics demonstrates exceptional 1008% revenue growth and maintains a strong debt-free balance sheet, indicating successful early commercialization. However, the company is burning $139.9M in free cash flow annually while generating only $62.4M in revenue, resulting in less than 1 year of cash runway at current burn rates. Operating losses of $111.3M on revenue of $62.4M indicate the company lacks operational leverage and faces unsustainable unit economics.
Why Buy Tango Therapeutics, Inc. Stock? TNGX Key Strengths
- Exceptional revenue growth of 1008% YoY suggests successful drug commercialization and market traction
- Pristine balance sheet with zero long-term debt and $346.2M stockholders' equity provides financial flexibility
- Strong liquidity position with $112.3M cash and 16.3x current ratio enables near-term operations
TNGX Stock Risks: Tango Therapeutics, Inc. Investment Risks
- Severe cash burn of $139.9M annually against only $62.4M revenue creates unsustainable 1-year cash runway without additional capital raises
- Operating margin of -178.4% indicates operating expenses far exceed revenue, with no visible path to profitability
- Typical biotech execution risks including regulatory, clinical trial failure, and competition in oncology pipeline
Key Metrics to Watch
- Operating cash burn rate and projected runway to profitability or next capital requirement
- Revenue sustainability and ability to scale to cover operating expenses
- Clinical trial progress and regulatory milestones for pipeline programs
Tango Therapeutics, Inc. (TNGX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 16.32x current ratio provides a solid financial cushion.
TNGX Profit Margin, ROE & Profitability Analysis
TNGX vs Healthcare Sector: How Tango Therapeutics, Inc. Compares
How Tango Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tango Therapeutics, Inc. Stock Overvalued? TNGX Valuation Analysis 2026
Based on fundamental analysis, Tango Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tango Therapeutics, Inc. Balance Sheet: TNGX Debt, Cash & Liquidity
TNGX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tango Therapeutics, Inc.'s revenue has grown significantly by 68% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.08 indicates the company is currently unprofitable.
TNGX Revenue Growth, EPS Growth & YoY Performance
TNGX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.6M | $15.9M | $0.13 |
| Q2 2025 | $3.2M | -$25.6M | $-0.24 |
| Q1 2025 | $5.4M | -$37.9M | $-0.35 |
| Q3 2024 | $10.7M | -$20.7M | $-0.23 |
| Q2 2024 | $14.6M | -$20.7M | $-0.23 |
| Q1 2024 | $5.8M | -$28.0M | $-0.32 |
| Q3 2023 | $6.9M | -$20.7M | $-0.23 |
| Q2 2023 | $5.8M | -$20.7M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tango Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TNGX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tango Therapeutics, Inc. (CIK: 0001819133)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TNGX
What is the AI rating for TNGX?
Tango Therapeutics, Inc. (TNGX) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TNGX's key strengths?
Claude: Exceptional revenue growth of 1008% YoY suggests successful drug commercialization and market traction. Pristine balance sheet with zero long-term debt and $346.2M stockholders' equity provides financial flexibility.
What are the risks of investing in TNGX?
Claude: Severe cash burn of $139.9M annually against only $62.4M revenue creates unsustainable 1-year cash runway without additional capital raises. Operating margin of -178.4% indicates operating expenses far exceed revenue, with no visible path to profitability.
What is TNGX's revenue and growth?
Tango Therapeutics, Inc. reported revenue of $62.4M.
Does TNGX pay dividends?
Tango Therapeutics, Inc. does not currently pay dividends.
Where can I find TNGX SEC filings?
Official SEC filings for Tango Therapeutics, Inc. (CIK: 0001819133) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TNGX's EPS?
Tango Therapeutics, Inc. has a diluted EPS of $-0.87.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TNGX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Tango Therapeutics, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TNGX stock overvalued or undervalued?
Valuation metrics for TNGX: ROE of -29.3% (sector avg: 15%), net margin of -162.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TNGX stock in 2026?
Our dual AI analysis gives Tango Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TNGX's free cash flow?
Tango Therapeutics, Inc.'s operating cash flow is $-138.9M, with capital expenditures of $1.0M. FCF margin is -224.3%.
How does TNGX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -162.9% (avg: 12%), ROE -29.3% (avg: 15%), current ratio 16.32 (avg: 2).